|
All patients
|
(n = 101)
|
(n = 109)
|
|
Baseline
|
230.6 (178.2 to 298.3)
|
205.3 (160.2 to 263.0)
|
|
Week 24
|
225.2 (174.1 to 291.3)
|
219.5 (171.3 to 281.2)
|
|
Proportional change from baseline to week 24
|
0.98 (0.89 to 1.08)
|
1.07 (0.97 to 1.18)
|
|
Naïve
|
(n = 36)
|
(n = 42)
|
|
Baseline
|
302.4 (206.7 to 442.5)
|
309.1 (217.3 to 439.6)
|
|
Week 24
|
277.3 (189.5 to 405.7)
|
298.9 (210.1 to 425.2)
|
|
Proportional change from baseline to week 24
|
0.92 (0.78 to 1.08)
|
0.97 (0.83 to 1.12)
|
|
Non-naïve
|
(n = 65)
|
(n = 67)
|
|
Baseline
|
198.4 (141.9 to 277.4)
|
158.8 (114.2 to 220.9)
|
|
Week 24
|
200.6 (143.5 to 280.5)
|
180.9 (130.1 to 251.6)
|
|
Proportional change from baseline to week 24
|
1.01 (0.89 to 1.14)
|
1.14 (1.01 to 1.29)
|
|
Non-naïve metformin user
|
(n = 15)
|
(n = 24)
|
|
Baseline
|
148.6 (67.2 to 328.6)
|
124.9 (66.7 to 233.9)
|
|
Week 24
|
167.3 (75.7 to 370.1)
|
158.3 (84.5 to 296.4)
|
|
Proportional change from baseline to week 24
|
1.13 (0.89 to 1.42)
|
1.27 (1.05 to 1.53)
|
|
Non-naïve DPP-4 inhibitor user
|
(n = 57)
|
(n = 57)
|
|
Baseline
|
213.9 (149.3 to 306.4)
|
164.0 (114.5 to 235.0)
|
|
Week 24
|
207.7 (145.0 to 297.5)
|
181.9 (127.0 to 260.5)
|
|
Proportional change from baseline to week 24
|
0.97 (0.85 to 1.11)
|
1.11 (0.97 to 1.26)
|
